Profound Medical Corp (PROF)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $271.77M
Last updated: Nov 17, 2026 at 11:06 AM ET
Profound Medical Corp (PROF) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Profound Medical reported EPS of -$0.21, below the -$0.19 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PROF's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
PROF Earnings Call
The latest PROF earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PROF beat 16, missed 22 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $9.83M, up 85.8% from $5.29M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.21 | -$0.19 | -$0.22 - -$0.16 | -10.53% | Miss | N/A | 4 | 2 up, 0 down | Nov 5, 2026 | $9.83M |
| Jun 30, 2026 | $0.26 | -$0.22 | -$0.29 - -$0.19 | +218.18% | Beat | N/A | 4 | 2 up, 2 down | Aug 6, 2026 | $2.48M |
| Mar 31, 2026 | -$0.19 | -$0.25 | -$0.31 - -$0.23 | +24.00% | Beat | N/A | 5 | 1 up, 1 down | May 7, 2026 | $5.34M |
| Dec 31, 2025 | -$0.27 | -$0.30 | -$0.30 - -$0.24 | +10.60% | Beat | N/A | 3 | 1 up, 0 down | Mar 5, 2026 | $5.98M |
| Sep 30, 2025 | -$0.26 | -$0.38 | -$0.44 - -$0.32 | +31.58% | Beat | N/A | 5 | 2 up, 0 down | Nov 13, 2025 | $5.29M |
| Jun 30, 2025 | -$0.52 | -$0.40 | -$0.47 - -$0.34 | -30.00% | Miss | N/A | 4 | 0 up, 1 down | Aug 14, 2025 | $2.21M |
| Mar 31, 2025 | -$0.36 | -$0.28 | -$0.31 - -$0.26 | -28.57% | Miss | N/A | 4 | 0 up, 2 down | May 8, 2025 | $2.62M |
| Dec 31, 2024 | -$0.20 | -$0.32 | -$0.39 - -$0.26 | +37.98% | Beat | N/A | 4 | 1 up, 1 down | Mar 6, 2025 | $4.18M |
| Sep 30, 2024 | -$0.38 | -$0.30 | -$0.35 - -$0.26 | -26.67% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2024 | $2.83M |
| Jun 30, 2024 | -$0.28 | -$0.28 | -$0.34 - -$0.25 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Aug 8, 2024 | $2.23M |
| Mar 31, 2024 | -$0.26 | -$0.31 | -$0.37 - -$0.26 | +16.13% | Beat | N/A | 4 | 0 up, 0 down | May 9, 2024 | $1.44M |
| Dec 31, 2023 | -$0.42 | -$0.32 | -$0.40 - -$0.23 | -31.25% | Miss | N/A | 7 | 0 up, 0 down | Mar 7, 2024 | $2.66M |
| Sep 30, 2023 | -$0.26 | -$0.32 | -$0.40 - -$0.31 | +18.75% | Beat | N/A | 5 | 0 up, 0 down | Nov 2, 2023 | $1.73M |
| Jun 30, 2023 | -$0.35 | -$0.34 | -$0.38 - -$0.28 | -2.94% | Miss | N/A | 6 | 0 up, 0 down | Aug 9, 2023 | $1.60M |
| Mar 31, 2023 | -$0.32 | -$0.34 | -$0.40 - -$0.25 | +5.88% | Beat | N/A | 5 | 0 up, 0 down | May 10, 2023 | $1.86M |
| Dec 31, 2022 | -$0.46 | -$0.36 | -$0.40 - -$0.31 | -27.78% | Miss | N/A | 5 | 0 up, 0 down | Mar 7, 2023 | $1.70M |
| Sep 30, 2022 | -$0.24 | -$0.38 | -$0.49 - -$0.23 | +36.84% | Beat | N/A | 6 | 0 up, 0 down | Nov 3, 2022 | $2.81M |
| Jun 30, 2022 | -$0.28 | -$0.39 | -$0.45 - -$0.36 | +28.21% | Beat | N/A | 7 | 0 up, 1 down | Aug 4, 2022 | $2.01M |
| Mar 31, 2022 | -$0.40 | -$0.43 | -$0.55 - -$0.37 | +6.98% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2022 | $1.71M |
| Dec 31, 2021 | -$0.49 | -$0.37 | -$0.46 - -$0.24 | -32.43% | Miss | N/A | 5 | 0 up, 0 down | Mar 3, 2022 | $1.26M |
| Sep 30, 2021 | -$0.29 | -$0.30 | -$0.36 - -$0.14 | +3.33% | Beat | N/A | 3 | N/A | Nov 4, 2021 | $3.21M |
| Jun 30, 2021 | -$0.35 | -$0.30 | N/A | -16.67% | Miss | N/A | N/A | N/A | Aug 4, 2021 | $2.60M |
| Mar 31, 2021 | -$0.37 | -$0.29 | N/A | -27.59% | Miss | N/A | N/A | N/A | May 12, 2021 | $893599 |
| Dec 31, 2020 | -$0.49 | -$0.43 | N/A | -13.95% | Miss | N/A | N/A | N/A | Mar 2, 2021 | $3.66M |
| Sep 30, 2020 | -$0.33 | -$0.24 | N/A | -37.50% | Miss | N/A | N/A | N/A | Nov 5, 2020 | $2.24M |
| Jun 30, 2020 | -$0.35 | -$0.21 | N/A | -66.67% | Miss | N/A | N/A | N/A | Aug 6, 2020 | $1.03M |
| Mar 31, 2020 | -$0.18 | -$0.26 | N/A | +30.77% | Beat | N/A | N/A | N/A | May 7, 2020 | $1.16M |
| Dec 31, 2019 | -$0.32 | -$0.49 | N/A | +34.80% | Beat | N/A | N/A | N/A | Mar 3, 2020 | $2.17M |
| Sep 30, 2019 | -$0.43 | -$0.38 | N/A | -13.16% | Miss | N/A | N/A | N/A | Nov 7, 2019 | $682224 |
| Jun 30, 2019 | -$0.38 | -$0.33 | N/A | -15.15% | Miss | N/A | N/A | N/A | Aug 14, 2019 | $437316 |
| Mar 31, 2019 | -$0.22 | -$0.33 | N/A | +33.33% | Beat | N/A | N/A | N/A | May 6, 2019 | $1.11M |
| Dec 31, 2018 | -$0.50 | -$0.45 | N/A | -11.11% | Miss | N/A | N/A | N/A | Mar 7, 2019 | $1.22M |
| Sep 30, 2018 | -$0.38 | -$0.34 | N/A | -11.76% | Miss | N/A | N/A | N/A | Nov 8, 2018 | $235032 |
| Jun 30, 2018 | -$0.38 | -$0.29 | N/A | -31.03% | Miss | N/A | N/A | N/A | Aug 14, 2018 | $162213 |
| Mar 31, 2018 | -$0.47 | -$0.31 | N/A | -51.61% | Miss | N/A | N/A | N/A | May 10, 2018 | $291414 |
| Dec 31, 2017 | -$0.60 | -$0.50 | N/A | -20.00% | Miss | N/A | N/A | N/A | Mar 26, 2018 | $1.89M |
| Sep 30, 2017 | -$0.70 | -$0.56 | N/A | -25.00% | Miss | N/A | N/A | N/A | Nov 7, 2017 | $1.47M |
| Jun 30, 2017 | -$0.08 | -$0.07 | N/A | -14.29% | Miss | N/A | N/A | N/A | Aug 23, 2017 | $957139 |
| Mar 31, 2017 | -$0.51 | -$0.52 | N/A | +1.92% | Beat | N/A | N/A | N/A | May 9, 2017 | $591517 |
| Dec 31, 2016 | -$0.07 | -$0.07 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 6, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.41, after -$1.12 the year before. It was -$1.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.41 | N/A |
| Dec 31, 2024 | -$1.12 | N/A |
| Dec 31, 2023 | -$1.35 | N/A |
| Dec 31, 2022 | -$1.38 | N/A |
| Dec 31, 2021 | -$1.50 | N/A |
| Dec 31, 2020 | -$1.35 | N/A |
| Dec 31, 2019 | -$1.35 | N/A |
| Dec 31, 2018 | -$1.73 | N/A |
| Dec 31, 2017 | -$1.89 | N/A |
| Dec 31, 2016 | -$1.62 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,398 | 11 | |
| 2026Q2 | Jun 30, 2026 | 5,776 | 10 | |
| 2025Q4 | Dec 31, 2025 | 6,912 | 11 | |
| 2025Q3 | Sep 30, 2025 | 5,182 | 9 | |
| 2025Q2 | Jun 30, 2025 | 6,627 | 11 | |
| 2025Q1 | Mar 31, 2025 | 5,797 | 10 | |
| 2024Q4 | Dec 31, 2024 | 4,548 | 8 | |
| 2024Q3 | Sep 30, 2024 | 5,628 | 9 |
2026Q3 Earnings Call
Opening remarks
Stephen Kilmer Investor Relations Thank you, operator, and good afternoon, everyone. Welcome to Profound Medical's Third Quarter 2026 Conference Call. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws in the United States and Canada. All forward-looking statements are based on Profound's current beliefs, assumptions and expectations, and relate to, among other things, current or future financial performance and position, our revenue and gross margin outlook, commercialization activities, customer utilization, product development, leadership succession and expectations regarding the efficacy of our technologies. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. No forward-looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these statements, which speak only as of today. Please review the risk factors described in our filings with the U.S. and Canadian securities regulators. Profound undertakes no obligation to publicly update or revise forward-looking statements, except as required by law. Joining us today are Dr. Arun Menawat, Chief Executive Officer and Chairman; Matthew Sobczyk, our Chief Financial Officer; Tom Tamberrino, our Chief Commercial Officer; Mathieu Burtnyk, our Chief Technology Officer; and Richard Fabian, our current President and incoming CEO. We have lots to discuss today. Matthew will begin with our financial results, followed by Rich on operational priorities and Tom on commercial progress. Arun will then provide a strategic update before we open the call to questions. Just a heads-up in that regard: Arun is just getting over a bad cold, so his voice might break up a bit here and there. With that, I'll turn the call over to Matthew.
Matthew Sobczyk CFO Good afternoon, everyone. On behalf of the management team and everyone at Profound, thank you for your continued interest and support. Before turning the call over to Rich for an operational update, I'll briefly review our third quarter 2026 financial results. For the three months ended September 30, 2026, Profound recorded total revenue of $9.8 million, up 86% from the third quarter of 2025. Revenue comprised $4.1 million of recurring noncapital revenue from single-use devices and service associated with extended warranties, and $5.7 million of capital equipment sales. Gross margin was 78% compared with 74% in the prior-year quarter, reflecting a favorable product mix and continued strong price discipline. Operating expenses were $15.5 million, an increase of 21% year over year. The increase primarily reflected increased headcount, increased commission expense driven by our revenue growth, travel expenditures and higher consulting expenditures due to spending on R&D initiatives to reduce product costs and improve efficiencies.
Frequently Asked Questions About PROF
Did PROF beat earnings estimates last quarter?
No. Profound Medical reported EPS of -$0.21 for the quarter ended Sep 30, 2026, below the -$0.19 estimate by 10.53%.
What EPS do analysts expect from PROF next quarter?
The consensus EPS estimate for Profound Medical for the quarter ending Dec 31, 2026 is -$0.19 from 5 analysts, with estimates from -$0.21 to -$0.19.
How often does PROF beat earnings estimates?
Profound Medical beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +31.66%.
PROF pages: Overview, Earnings, Forecast, Financials